secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273329
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics Q3 net loss widens to $106M; CASGEVY momentum builds, CTX310 Phase 1 data positive
--------------------------------------------------------------------------------

- Q3 net loss $106.4M vs $85.9M YoY; cash & equivalents $1.94B (flat vs Dec 2024).
- CASGEVY: 165 patients completed cell collection, 39 infused; Vertex expects >$100M revenue in 2025.
- CTX310 Phase 1 data at AHA/NEJM show durable TG and LDL reduction; advancing to Phase 1b.
- CTX460 (SyNTase) preclinical data >90% mRNA correction in AATD; trial planned mid-2026.
- SRSD107 Phase 2 first patient dosed for thromboembolic disorders; trial expanded in Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312525273329/0001193125-25-273329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312525273329/crsp-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer